Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-22

FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Bionpharma Inc.)

View source ↗

Summary

FDA approved a supplemental application for divalproex sodium submitted by Bionpharma Inc. under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DIVALPROEX SODIUM (divalproex sodium)

Snippet

SUPPL AP for DIVALPROEX SODIUM (DIVALPROEX SODIUM)